Malin Corporation PLC Notice of 2024 Interim Results

RNS Number : 9910A

Malin Corporation PLC

20 August 2024

 

Malin Corporation plc

 

Notice of 2024 Interim Results

 

Dublin-Ireland, 20 August 2024: Malin Corporation plc. (Euronext Growth Dublin:MLC) ("Malin" or "the Company"), a company investing in highly innovative life sciences companies, intends to report its interim financial results and publish its interim report for the six month period ended 30 June 2024 at 07:00am Irish Standard Time/BST on Tuesday, 27 August 2024.

 

The Company's interim report and results press release will be available on the Company's website at 07:00am Irish Standard Time/BST on 27 August 2024 at www.malinplc.com.

ENDS

About Malin Corporation plc

Malin (Euronext Growth Dublin:MLC) is a company investing in highly innovative life sciences companies. Its purpose is to create shareholder value through the application of long-term capital and operational and strategic expertise to a diverse range of global healthcare businesses. Malin has a focus on innovative businesses underpinned by exceptional science and works with its investee companies, providing strategic and financial support to enable them to reach their value potential. Malin is headquartered and domiciled in Ireland and listed on the Euronext Growth Dublin. For more information visit www.malinplc.com 

For further information please contact:

 

Malin

Fiona Dunlevy, Executive Director/Company Secretary

Tel: [phone]

[e-mail]

 

Davy Corporate Finance (Euronext Growth Listing Sponsor & Broker)

Brian Garrahy / Daragh O'Reilly

Tel: [phone]

 

Sodali & Co (Media enquiries)         

Eavan Gannon

Tel: [phone]                            

[e-mail]  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NORFLFFRTDIALIS